Last reviewed · How we verify
amoxicillin/clavulanate potassium 1gm
amoxicillin/clavulanate potassium 1gm is a Beta-lactam antibiotic with beta-lactamase inhibitor Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin. Used for Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.
At a glance
| Generic name | amoxicillin/clavulanate potassium 1gm |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Clavulanate potassium is a beta-lactamase inhibitor that protects amoxicillin from degradation by bacterial beta-lactamase enzymes, thereby extending amoxicillin's spectrum of activity to include beta-lactamase-producing organisms.
Approved indications
- Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reactions (including anaphylaxis)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amoxicillin/clavulanate potassium 1gm CI brief — competitive landscape report
- amoxicillin/clavulanate potassium 1gm updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about amoxicillin/clavulanate potassium 1gm
What is amoxicillin/clavulanate potassium 1gm?
How does amoxicillin/clavulanate potassium 1gm work?
What is amoxicillin/clavulanate potassium 1gm used for?
Who makes amoxicillin/clavulanate potassium 1gm?
What drug class is amoxicillin/clavulanate potassium 1gm in?
What development phase is amoxicillin/clavulanate potassium 1gm in?
What are the side effects of amoxicillin/clavulanate potassium 1gm?
What does amoxicillin/clavulanate potassium 1gm target?
Related
- Drug class: All Beta-lactam antibiotic with beta-lactamase inhibitor drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs); bacterial beta-lactamase
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections
- Compare: amoxicillin/clavulanate potassium 1gm vs similar drugs
- Pricing: amoxicillin/clavulanate potassium 1gm cost, discount & access